Home
/
ImmunityBio, Inc.
/
Financials
/
Quarterly
ImmunityBio, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that ImmunityBio, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$32.06M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$26.43M
Aug 5, 2025
Q1
2025
Mar 31, 2025
$16.52M
May 12, 2025
Q3
2025
Sep 30, 2024
$6.11M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$1.05M
Aug 5, 2025
Q1
2025
Mar 31, 2024
$40.0K
May 12, 2025
Q3
2023
Sep 30, 2023
$82.0K
Nov 9, 2023
Q2
2023
Jun 30, 2023
$41.0K
Aug 8, 2023
Q1
2024
Mar 31, 2023
$360.0K
May 9, 2024
Q3
2023
Sep 30, 2022
$118.0K
Nov 9, 2023
Q2
2023
Jun 30, 2022
$35.0K
Aug 8, 2023
Q1
2023
Mar 31, 2022
$14.0K
May 11, 2023
Q3
2022
Sep 30, 2021
$66.0K
Nov 9, 2022
Q2
2022
Jun 30, 2021
$339.0K
Aug 8, 2022
Q3
2021
Mar 31, 2021
$139.0K
Nov 12, 2021
Q1
2022
Mar 31, 2021
$139.0K
May 10, 2022
Q2
2021
Mar 31, 2021
$139.0K
Aug 12, 2021
Q3
2021
Sep 30, 2020
$151.0K
Nov 12, 2021
Q2
2021
Jun 30, 2020
$436.0K
Aug 12, 2021
Q1
2021
Mar 31, 2020
$165.0K
May 14, 2021
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$32.06M
Nov 5, 2025
Q2
2025
Jun 30, 2025
$26.43M
Aug 5, 2025
Q1
2025
Mar 31, 2025
$16.52M
May 12, 2025
Q3
2025
Sep 30, 2024
$6.11M
Nov 5, 2025
Q2
2025
Jun 30, 2024
$1.05M
Aug 5, 2025
Q1
2025
Mar 31, 2024
$40.0K
May 12, 2025
Q3
2024
Sep 30, 2023
$82.0K
Nov 12, 2024
Q2
2024
Jun 30, 2023
$41.0K
Aug 12, 2024
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($67.25M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($92.56M)
Aug 5, 2025
Q1
2025
Mar 31, 2025
($129.65M)
May 12, 2025
Q3
2025
Sep 30, 2024
($85.73M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($134.56M)
Aug 5, 2025
Q1
2025
Mar 31, 2024
($134.11M)
May 12, 2025
Q3
2024
Sep 30, 2023
($95.58M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($137.88M)
Aug 12, 2024
Q1
2024
Mar 31, 2023
($116.34M)
May 9, 2024
Q3
2023
Sep 30, 2022
($110.94M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($94.59M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($102.83M)
May 11, 2023
Q3
2022
Sep 30, 2021
($87.63M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($88.29M)
Aug 8, 2022
Q1
2022
Mar 31, 2021
($79.61M)
May 10, 2022
Q3
2021
Sep 30, 2020
($65.60M)
Nov 12, 2021
Q2
2021
Jun 30, 2020
($51.44M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($37.04M)
May 14, 2021
Q3
2020
Sep 30, 2019
($15.58M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($16.68M)
Aug 7, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($55.63M)
Nov 5, 2025
Q2
2025
Jun 30, 2025
($71.29M)
Aug 5, 2025
Q1
2025
Mar 31, 2025
($64.43M)
May 12, 2025
Q3
2025
Sep 30, 2024
($80.25M)
Nov 5, 2025
Q2
2025
Jun 30, 2024
($99.33M)
Aug 5, 2025
Q1
2025
Mar 31, 2024
($95.20M)
May 12, 2025
Q3
2024
Sep 30, 2023
($80.14M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($85.15M)
Aug 12, 2024
Q1
2024
Mar 31, 2023
($111.58M)
May 9, 2024
Q3
2023
Sep 30, 2022
($90.80M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($79.62M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($95.97M)
May 11, 2023
Q3
2022
Sep 30, 2021
($78.84M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($85.91M)
Aug 8, 2022
Q1
2022
Mar 31, 2021
($86.26M)
May 10, 2022
Q2
2021
Mar 31, 2021
($86.26M)
Aug 12, 2021
Q3
2021
Mar 31, 2021
($86.26M)
Nov 12, 2021
Q3
2021
Sep 30, 2020
($65.88M)
Nov 12, 2021
Q2
2021
Jun 30, 2020
($50.92M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($36.70M)
May 14, 2021